Disease	CAR T-cell strategy	Examples of studies
Hematological malignancies
B-cell and B-precursor ALL	CD19, CD22, CD19/CD22-specific CAR T cells	NCT04499573,[@405841] NCT06343090,[@405851] NCT02614066,[@405852] NCT06647329[@405853]
NHL (DLBCL, HGBCL, PMBCL, FL, TFL, MZL, MCL)	CD19, CD19/CD22 CAR T cells (including in combination with PD-1 antibodies)	NCT02348216,[@405854] NCT02926833,[@405855] NCT03287817,[@405856] NCT02601313,[@405857] NCT02631044,[@405858] NCT03310619,[@405859] NCT03568461,[@405860] NCT03105336,[@405861] NCT06647329[@405853]
Multiple myeloma	BCMA- and GPRC5D-specific CAR T cells	NCT04271644,[@405862] NCT04133636,[@405863] NCT03318861,[@405864] NCT04555551,[@405865] NCT04155749,[@405866] NCT03288493[@405867]
Solid tumors
HER2-positive sarcoma	HER2-specific CAR T cells	NCT00902044[@405868]
Neuroblastoma	GD-2-specific CAR T cells	NCT01822652[@405869]
Pancreatic cancer	Mesothelin/GPC3/GUCY2C-specific CAR T cells, autologous CAR T cells targeting B7-H3	NCT05779917,[@405870] NCT06158139[@405871]
GD2- and PSMA-positive tumors	GD2/PSMA-specific CAR T cells	NCT05437315[@405872]